文献速递神经肿瘤

组间研究NCCTG 86-72-51(Alliance)最终报告:成人低级别胶质瘤高剂量与低剂量放疗的III期随机临床试验

Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma.
PubMed 文献 · Neuro Oncol · 2020-01-01

该III期随机试验将203例成人幕上低级别胶质瘤患者按1:1随机分配至50.4 Gy/28次或64.8 Gy/36次放疗,中位随访17.2年。高剂量放疗未改善15年总生存(22.4% vs 24.9%,P=0.978)或无进展生存(15.2% vs 9.5%,P=0.7142)。长期随访显示高剂量较低剂量放疗无获益,认知功能(MMSE)在放疗后保持稳定。

要点

  • 高剂量放疗未改善15年总生存(22.4% vs 24.9%,P=0.978)。
  • 高剂量放疗未改善15年无进展生存(15.2% vs 9.5%,P=0.7142)。
  • 基线MMSE正常者放疗后7年仅1例(5%)MMSE较前次显著下降。

核心结论

  • 长期随访表明高剂量放疗较低剂量放疗对低级别胶质瘤无获益。
  • 以MMSE衡量,放疗后认知功能保持稳定。

研究设计与样本

  • III期随机临床试验,1986年至1994年纳入203例幕上低级别胶质瘤患者,按1:1随机分配至50.4 Gy/28次或64.8 Gy/36次放疗,放疗前接受任何程度切除。

主要发现

  • 全部患者中位总生存为8.4年(95%CI:7.2-10.8),中位无进展生存为5.2年(95%CI:4.3-6.6)。
  • 33例仍存活患者的中位随访时间为17.2年。
  • 高剂量放疗组15年总生存22.4% vs 低剂量放疗组24.9%(log-rank P=0.978)。
  • 高剂量放疗组15年无进展生存15.2% vs 低剂量放疗组9.5%(P=0.7142)。
  • 术前肿瘤直径<5 cm、基线简易精神状态检查(MMSE)>27且接受全切除术的患者总生存显著更好;少突胶质细胞瘤 vs 星形细胞瘤、术前肿瘤直径<5 cm、接受全切除术及基线MMSE>27的患者无进展生存改善。

关键数值与推荐

  • 基线MMSE正常者中,7年时仅1例(5%)MMSE较前次时间点出现临床显著下降,其余(95%)稳定。
  • 10年、12年或15年时均无MMSE下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal radiation dose for adult supratentorial low-grade glioma is unknown. The aim of this study was to provide a final update on oncologic and cognitive outcomes of high-dose versus low-dose radiation for low-grade glioma. METHODS: Between 1986 and 1994, 203 patients with supratentorial low-grade glioma were randomized (1:1) to 50.4 Gy in 28 fractions versus 64.8 Gy in 36 fractions after any degree of resection. RESULTS: For all patients, median overall survival (OS) was 8.4 years (95% CI: 7.2-10.8). Median progression-free survival (PFS) was 5.2 years (95% CI: 4.3-6.6). Median follow-up is 17.2 years for the 33 patients still alive. High-dose radiation did not improve 15-year OS (22.4%) versus low-dose radiation (24.9%, log-rank P = 0.978) or 15-year PFS (high dose, 15.2% vs low dose, 9.5%; P = 0.7142). OS was significantly better for patients with preoperative tumor diameter <5 cm and baseline Mini-Mental State Examination (MMSE) >27 and who underwent gross total resection. PFS was improved for patients with oligodendroglioma versus astrocytoma, preoperative tumor diameter <5 cm, patients who had gross total resection, and patients with baseline MMSE >27. For patients who had normal MMSE at baseline, at 7 years only 1 patient (5%) had a clinically significant decrease in MMSE from the previous time point, with the remainder (95%) stable. None had decrease in MMSE at 10, 12, or 15 years. CONCLUSIONS: Long-term follow-up indicates no benefit to high-dose over low-dose radiation for low-grade gliomas. Cognitive function appeared to be stable after radiation as measured by MMSE.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Breen WG, Anderson SK, Carrero XW, et al. Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. Neuro Oncol. 2020. PMID: 32002556. doi:10.1093/neuonc/noaa021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。